Dimension Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch DMTX and buy or sell other stocks, ETFs, and their options commission-free!

About DMTX

Dimension Therapeutics, Inc. engages in the development of novel treatments for rare diseases. Its activities include discoveries and development of therapeutic products for people living with rare diseases associated wit the liver and caused by genetic mutations. 

CEO
Annalisa Mary Jenkins, PhD
CEOAnnalisa Mary Jenkins, PhD
Employees
Employees
Headquarters
Cambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded
2013
Founded2013
Employees
Employees

DMTX Key Statistics

Market cap
149.99M
Market cap149.99M
Price-Earnings ratio
-2.67
Price-Earnings ratio-2.67
Dividend yield
Dividend yield
Average volume
28.04K
Average volume28.04K
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$6.10
52 Week high$6.10
52 Week low
$1.05
52 Week low$1.05

Stock Snapshot

With a market cap of 149.99M, Dimension Therapeutics(DMTX) trades at $5.95. The stock has a price-to-earnings ratio of -2.67.

On 2026-03-31, Dimension Therapeutics(DMTX) shares started trading at —, with intraday highs of — and lows of —.

Trading activity shows a volume of 0, compared to an average daily volume of 28.04K.

The stock's 52-week range extends from a low of $1.05 to a high of $6.10.

The stock's 52-week range extends from a low of $1.05 to a high of $6.10.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.